Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

EPIK-O/ENGOT-OV61: Alpelisib Plus Olaparib vs Cytotoxic Chemotherapy in High-Grade Serous Ovarian Cancer (Phase III Study)

2022; Future Medicine; Volume: 18; Issue: 31 Linguagem: Inglês

10.2217/fon-2022-0666

ISSN

1744-8301

Autores

Panagiotis A. Konstantinopoulos, Antonio González‐Martín, Felipe Melo Cruz, Michael Friedlander, Rosalind Glasspool, Domenica Lorusso, Christian Marth, Bradley J. Monk, Jae‐Weon Kim, Patsy Hinson, Olga Ajipa, Vincent Prêtre, Yu Han, Ursula A. Matulonis,

Tópico(s)

Toxin Mechanisms and Immunotoxins

Resumo

Patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and their management represents a substantial unmet medical need. Preclinical data and results from a phase Ib trial demonstrated the efficacy and tolerability of the combination of the α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor alpelisib plus the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib in platinum-resistant, non-

Referência(s)